Intravenous Immunoglobulin Market Top Players - Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031"

The global Intravenous Immunoglobulin market is estimated to reach over USD 21.38 billion by the year 2031, exhibiting a CAGR of 6.70% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1874

Immunoglobulins are produced from pooled human plasma, typically collected from a minimum of 100 donors to ensure therapeutic efficacy. While intramuscular administration was historically the standard approach, its use has declined due to associated discomfort. In recent years, intravenous immunoglobulin (IVIG) therapy has emerged as a critical treatment modality for patients with weakened or compromised immune systems. The rising incidence of target conditions such as primary immunodeficiency disorders is expected to be a key driver of market growth. Furthermore, factors including the growing prevalence of immunodeficiency diseases, advancements in medical technologies, increased investments in healthcare, broader acceptance of immunoglobulin-based treatments, and an aging global population are anticipated to contribute positively to revenue generation in this sector.

IVIG is a sterile, concentrated antibody solution derived from the plasma of healthy donors, administered intravenously to manage immune deficiencies and modulate immune responses. Despite its clinical importance, the market faces constraints due to the substantial costs involved in diagnosing and managing conditions like demyelinating diseases. Typically, IVIG treatments are administered every 3 to 4 weeks, amounting to 12 to 16 sessions annually. The average cost of IVIG therapy is approximately USD 73.89 per gram, with total treatment expenses potentially reaching USD 10,000 annually, depending on the severity and specific needs of the patient.

List of Prominent Players in the Intravenous Immunoglobulin Market:
• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc

Market Dynamics:
Drivers-
The rise in the geriatric population, the increased acceptance of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders are all key drivers driving the market growth. With new product launches and approvals, the immunoglobulin market is expected to develop in the future. IVIG therapies are in high demand for treating acquired and primary immunodeficiency illnesses since they are the most effective and only viable therapy option. Furthermore, inactive lifestyle practices, such as eating saturated fats, salt, and sweets, as well as a deficiency of physical exercise and excessive alcohol use, have contributed to an increase in the prevalence of these diseases.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Challenges:
The elevated cost of intravenous immunoglobulin (IVIG) therapy represents a major obstacle to its broader adoption, potentially restricting market growth throughout the forecast period. In addition, disruptions in the supply chain-primarily due to limited availability of raw materials-pose operational risks. Regulatory complexities and stringent compliance requirements across different jurisdictions further complicate market entry and expansion efforts. Immunoglobulin therapy is among the most sophisticated and resource-intensive treatment modalities, with substantial expenses associated with plasma collection, purification processes, and the need for cutting-edge technology and robust healthcare infrastructure. These factors collectively contribute to ongoing challenges within the global plasma supply chain, particularly in regions with limited access to advanced healthcare resources.

Regional Trends:
The North American market for intravenous immunoglobulin is poised to secure a leading share of global revenues and is projected to grow at a robust compound annual growth rate (CAGR) over the forecast period. This expansion is supported by the region's highly developed healthcare infrastructure, strong emphasis on research and innovation, and the presence of prominent industry stakeholders. Meanwhile, the Asia Pacific region is also demonstrating notable growth potential, fueled by rising awareness of immunoglobulin therapies and the increasing demand for treatment of primary immunodeficiencies, especially in aging populations.

Recent Developments:
• In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
• In January 2022, Argenx SE, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) had approved VYVGART (efgartigimod alfa) intravenous infusion for the therapy of adult patients with generalized myasthenia gravis (gMG) who have not answered adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1874

Segmentation of Intravenous Immunoglobulin Market-
By Application-
• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others
By Distribution Channel-
• Hospital Pharmacy
• Specialty Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/intravenous-immunoglobulin-market-/1874

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.